Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nyxoah (NYXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NYXH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.77
1 Year Target Price $12.77
| 3 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.16% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 254.60M USD | Price to earnings Ratio - | 1Y Target Price 12.77 |
Price to earnings Ratio - | 1Y Target Price 12.77 | ||
Volume (30-day avg) 5 | Beta 0.65 | 52 Weeks Range 5.55 - 11.87 | Updated Date 08/15/2025 |
52 Weeks Range 5.55 - 11.87 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-18 | When - | Estimate -0.6459 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1939.76% |
Management Effectiveness
Return on Assets (TTM) -33.76% | Return on Equity (TTM) -77.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 198913138 | Price to Sales(TTM) 58.34 |
Enterprise Value 198913138 | Price to Sales(TTM) 58.34 | ||
Enterprise Value to Revenue 38.92 | Enterprise Value to EBITDA -2 | Shares Outstanding 37441100 | Shares Floating 15727311 |
Shares Outstanding 37441100 | Shares Floating 15727311 | ||
Percent Insiders 41.73 | Percent Institutions 24.73 |
Upturn AI SWOT
Nyxoah
Company Overview
History and Background
Nyxoah S.A. was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. It is a medical technology company focused on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA). The company has evolved from initial research to a publicly traded company with a commercially available product.
Core Business Areas
- Therapeutic Solutions: Developing and commercializing neurostimulation solutions for the treatment of OSA.
- Medical Devices: Manufacturing and distributing medical devices related to their neurostimulation therapy.
Leadership and Structure
Olivier Taelman is the CEO. The company has a board of directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- Genio System: A bilateral hypoglossal nerve stimulation therapy for OSA. It delivers mild stimulation to the tongue, preventing airway collapse during sleep. Market share is still developing as the therapy is relatively new. Competitors include Inspire Medical Systems (INSP) and traditional CPAP therapy from companies like ResMed (RMD).
Market Dynamics
Industry Overview
The sleep apnea market is large and growing, driven by an aging population, increasing obesity rates, and rising awareness of OSA's health consequences. The industry includes CPAP devices, oral appliances, and surgical interventions.
Positioning
Nyxoah is positioned as an innovative alternative to traditional CPAP therapy for patients who are non-compliant or unwilling to use CPAP. They compete with Inspire Medical Systems, which offers a similar hypoglossal nerve stimulation therapy.
Total Addressable Market (TAM)
The estimated TAM for OSA treatment is substantial, potentially exceeding $10 billion globally. Nyxoah is targeting a subset of the CPAP-intolerant population, representing a significant market opportunity. Their Genio system is well placed to take part of this TAM
Upturn SWOT Analysis
Strengths
- Innovative technology (Genio system)
- Alternative to CPAP for non-compliant patients
- Demonstrated efficacy in clinical trials
- Bilateral stimulation allows for anatomical variations
Weaknesses
- Relatively new product with limited market penetration
- High cost of therapy compared to CPAP
- Requires surgical implantation
- Dependence on insurance coverage and reimbursement approvals
Opportunities
- Expanding market awareness of Genio system
- Securing broader insurance coverage
- Developing next-generation neurostimulation technology
- Partnerships with sleep clinics and healthcare providers
Threats
- Competition from Inspire Medical Systems (INSP)
- Technological advancements in CPAP therapy
- Regulatory changes impacting reimbursement
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- INSP
- RMD
Competitive Landscape
Nyxoah faces significant competition from established players like Inspire Medical Systems and ResMed. Its competitive advantage lies in its bilateral stimulation technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased sales of the Genio system.
Future Projections: Analyst projections forecast continued revenue growth as Nyxoah expands its market reach and secures broader insurance coverage. But there are challenges ahead.
Recent Initiatives: Recent initiatives include expanding the sales team, launching new clinical trials, and pursuing regulatory approvals in new markets.
Summary
Nyxoah is a growing medical device company with an innovative solution for OSA. It has high-growth potential but faces challenges related to market adoption, competition, and reimbursement. The company is well-positioned to capture a share of the growing sleep apnea market. However, it needs to carefully manage its cash burn and demonstrate sustained sales growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nyxoah
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-02 | CEO & Executive Director Mr. Olivier Taelman | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 183 | Website https://www.nyxoah.com |
Full time employees 183 | Website https://www.nyxoah.com | ||
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.